Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease

Gemphire Therapeutics (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis, announced today initiation of a Phase 2a proof-of-concept clinical trial investigating gemcabene as a treatment for pediatric nonalcoholic fatty liver disease.

As quoted in the press release:

“We are very excited to initiate this pediatric POC clinical trial as the next step in our program to evaluate gemcabene as a highly differentiated treatment for NAFLD and NASH in both adults and adolescents.  We believe gemcabene, based on its favorable safety profile and novel mechanism targeting the underlying pathologies of both dyslipidemia and inflammation, will have a distinct competitive advantage,” said Steven Gullans, Ph.D., Interim President and CEO of Gemphire.

Click here to read the full press release.